Aperio Group’s Aimmune Therapeutics AIMT Stock Holding History

Aperio Group’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,089	Closed	-$313K	–	2468
2020 Q3	$313K	Buy	+9,089	New	+$194K	﹤0.01%	2058
2020 Q1	–	Sell	-9,124	Closed	-$305K	–	2430
2019 Q4	$305K	Buy	+9,124	New	+$255K	﹤0.01%	2054
2019 Q3	–	Sell	-3,662	Closed	-$76K	–	2958
2019 Q2	$76K	Buy	+3,662	New	+$75.4K	﹤0.01%	2460

Aperio Group's AIMT Position: Q4 2020 in Review

Aperio Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 9,089 shares — an estimated $313K sold.

Aperio Group first reported a position in AIMT in Q2 2019 and held it in 3 quarters. The position peaked at $313K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Aperio Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Aperio Group sold 9,089 Aimmune Therapeutics shares in Q4 2020, an estimated $313K.
Aperio Group first reported a position in Aimmune Therapeutics in Q2 2019 and held it in 3 quarters.
Aperio Group's Aimmune Therapeutics position peaked at $313K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.